Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy
- PMID: 23791878
- DOI: 10.1016/j.canlet.2013.06.009
Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy
Abstract
Adoptive cell therapy provides an attractive treatment of cancer, and our expanding capacity to target tumor antigens is driven by genetically engineered human T lymphocytes that express genes encoding tumor-specific T cell receptors (TCRs). The intrinsic properties of cultured T cells used for therapy were reported to have tremendous influences on their persistence and antitumor efficacy in vivo. In this study, we isolated CD8(+) central memory T cells from peripheral blood lymphocytes of healthy donors, and then transferred with the gene encoding TCR specific for tumor antigen using recombinant adenovirus vector Ad5F35-TRAV-TRBV. We found effector T cells derived from central memory T cells improved cell viability, maintained certain level of CD62L expression, and reacquired the CD62L(+)CD44(high) phenotype of central memory T cells after effector T cells differentiation. We then compared the antitumor reactivity of central memory T cells and CD8(+)T cells after TCR gene transferred. The results indicated that tumor-specific TCR gene being transferred to central memory T cells effectively increased the specific killing of antigen positive tumor cells and the expression of cytolytic granule protein. Furthermore, TCR gene transferred central memory T cells were more effective than TCR gene transferred CD8(+)T cells in CTL activity and effector cytokine secretion. These results implicated that isolating central memory T cells rather than CD8(+)T cells for insertion of gene encoding tumor-specific TCR may provide a superior tumor-reactive T cell population for adoptive transfer.
Keywords: AFP; CAR; CD8(+)T cell; CTL; Calcein-AM; IFN-γ; IL-2; Immunotherapy; LNs; T cell receptor; T(CM); T(EM); TCR; TE; TIL; TM; TN; Transfer; alpha-fetoprotein; calcein–acetoxymethyl ester; central memory T cell; coxsackie/adenovirus receptors; cytotoxic lymphocytes; effector T cell; effector memory T cell; interferon-gamma; interlukin-2; lymph nodes; mAb; memory T cell; monoclonal antibody; naïve T cell; tumor-infiltrating lymphocyte.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Exploiting T cell receptor genes for cancer immunotherapy.Clin Exp Immunol. 2005 Feb;139(2):167-72. doi: 10.1111/j.1365-2249.2005.02715.x. Clin Exp Immunol. 2005. PMID: 15654813 Free PMC article. Review.
-
Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.Clin Immunol. 2005 Feb;114(2):119-29. doi: 10.1016/j.clim.2004.11.005. Clin Immunol. 2005. PMID: 15639645
-
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.Cancer Res. 2005 Feb 15;65(4):1570-6. doi: 10.1158/0008-5472.CAN-04-2076. Cancer Res. 2005. PMID: 15735047
-
Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.Anticancer Res. 2005 Mar-Apr;25(2A):715-24. Anticancer Res. 2005. PMID: 15868901
-
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Int Rev Immunol. 2015. PMID: 25901860 Review.
Cited by
-
Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care.Cells. 2021 Apr 5;10(4):808. doi: 10.3390/cells10040808. Cells. 2021. PMID: 33916369 Free PMC article. Review.
-
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8. J Hematol Oncol. 2020. PMID: 32894185 Free PMC article. Clinical Trial.
-
Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.Front Immunol. 2023 Jun 5;14:1186383. doi: 10.3389/fimmu.2023.1186383. eCollection 2023. Front Immunol. 2023. PMID: 37342333 Free PMC article. Review.
-
Machine learning-based identification of a consensus immune-derived gene signature to improve head and neck squamous cell carcinoma therapy and outcome.Front Pharmacol. 2024 Apr 10;15:1341346. doi: 10.3389/fphar.2024.1341346. eCollection 2024. Front Pharmacol. 2024. PMID: 38666027 Free PMC article.
-
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.Sci Transl Med. 2019 Mar 6;11(482):eaav1648. doi: 10.1126/scitranslmed.aav1648. Sci Transl Med. 2019. PMID: 30842314 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous